DSS (DSS) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Operates five main business lines: product packaging, biotechnology, commercial lending, direct marketing, and securities/investment management, with primary operations in North America and Asia.
Product packaging focuses on custom folding cartons, security printing, and sustainable packaging solutions.
Biotechnology division invests in drug discovery, prevention, and treatment of diseases, with a focus on licensing and global distribution.
Commercial lending provides business loans and is shifting focus toward inventory/equipment and broker/dealer loans.
Securities and investment management includes REITs, broker dealers, and mutual funds, with a growing presence in healthcare real estate.
Financial performance and metrics
Premier Packaging Corporation reported a 126% year-over-year increase in net income, attributed to strategic investments and operational improvements.
American Pacific Bancorp issued over $14 million in new loans and $4 million in renewals in the past 18 months, maintaining a managed loan portfolio exceeding $22 million.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for general corporate purposes, including working capital.
Latest events from DSS
- $10M shelf registration supports a multi-division growth strategy and future public offerings.DSS
Registration Filing16 Dec 2025 - Shareholders will elect directors, ratify the auditor, and vote on executive pay, with major ownership concentrated.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, and executive pay, with strong board oversight.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, compensation, and major shareholder control.DSS
Proxy Filing2 Dec 2025 - Revenue up 22% year-over-year, net loss narrows, but going concern risk persists.DSS
Q3 202514 Nov 2025 - Revenue up 27% and net loss narrowed, but going concern risk persists.DSS
Q2 202514 Aug 2025 - Q3 revenue rose 34% year-over-year, but nine-month revenue fell 28% as net losses narrowed.DSS
Q3 202413 Jun 2025 - Revenue and net loss improved sequentially as cost cuts and asset sales offset segment declines.DSS
Q2 202413 Jun 2025 - DSS, Inc. posted a $46.9M net loss in 2024, but completed the Impact BioMedical IPO.DSS
Q4 20249 Jun 2025